BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 6, 2012
View Archived Issues
Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial
Read More
Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer
Read More
FDA grants orphan drug status to Del Mar Pharmaceuticals product
Read More
Magnetic resonance techniques detect metabolic biomarker of low-grade glioma
Read More
Intellect Neurosciences provides pipeline update
Read More
Novo Nordisk completes phase I trial of novel oral insulin
Read More
Prima BioMed begins enrollment in CANVAS study
Read More
Merck KGaA claims new ALK5 inhibitors
Read More
Brazilian university patents new products with anticancer potential
Read More
Bayer Schering designs novel activators of soluble guanylate cyclase
Read More
OGX-427 shows signs of efficacy in phase II trial
Read More
Phase II trial assesses RO-4929097 in prostate cancer
Read More
Alpharadin available through new expanded access program
Read More
Pfizer designs novel liver X receptor modulators
Read More
Phase II GFT-505 study meets all efficacy objectives
Read More
Clinuvel Pharmaceuticals files MAA for erythropoietic protoporphyria treatment
Read More
Novel beta1-adrenoceptor ligands synthesized in U.K.
Read More
Novel PI3K inhibitors disclosed by Novartis
Read More
FDA accepts IND for Ziopharm product
Read More
FDA lifts partial clinical hold on hepatitis C therapy
Read More
FDA advisory committee sets date to review Marqibo NDA
Read More
Biogen Idec and Sobi release details of revised hemophilia program agreement
Read More
Oryzon choses drug candidate to begin preclinical testing for Huntington's disease
Read More